Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Aethlon Medical, Inc. (Nasdaq: AEMD), a San Diego-based medical therapeutic company, has announced a follow-on offering of 5,633,009 shares of its common stock and accompanying warrants, priced at a combined public offering price of $0.7101 per share. The gross proceeds from this offering are expected to total approximately $4 million, with the closing anticipated on or about July 7, 2026, subject to customary closing conditions. Maxim Group LLC is serving as the sole placement agent for this transaction.

Aethlon Medical specializes in developing innovative products aimed at treating cancer and life-threatening infectious diseases. Central to its portfolio is the Hemopurifier, an immunotherapeutic device designed to remove harmful viruses and exosomes from the bloodstream. This technology has garnered significant attention, particularly due to its potential applications in oncology and infectious disease treatment. The Hemopurifier has received FDA Breakthrough Device designation, underscoring its promise in addressing conditions that currently lack effective therapies.

The strategic rationale behind this fundraising effort is to bolster Aethlon's financial position to support ongoing research and development, clinical trials, and general corporate purposes. The company may also allocate a portion of the proceeds toward in-licensing or acquiring complementary technologies and assets, which could enhance its product offerings and market reach. Given the competitive landscape of the medical therapeutics sector, securing additional capital is crucial for companies like Aethlon to advance their clinical programs and maintain operational momentum.

The broader market dynamics for medical therapeutics remain robust, driven by a growing demand for innovative treatments in oncology and infectious diseases. As the healthcare landscape evolves, companies that can effectively leverage their technology and secure funding for development will likely be well-positioned for growth. Aethlon's follow-on offering reflects a proactive approach to capitalizing on these trends, as it seeks to enhance its capabilities and expedite the development of its breakthrough therapies.

Overall, the successful completion of this offering could signal increased investor confidence in Aethlon Medical's strategic direction and technological advancements. As the company continues to navigate the complexities of the medical therapeutics market, its ability to execute on its business plan will be critical in determining its long-term success and impact on patient care.